MedTrace Logo

The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma

NCT06659224 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2631

Last updated 2025-07-23

No results posted yet for this study

Summary

Ewing's sarcoma is an uncommon yet vital malignancy of bone. It demonstrates a predilection for the pediatric and young adult population. Chemotherapy is considered an important treatment modality for Ewing's sarcoma. However, the development of therapy-related leukemia, especially acute myeloid leukemia following treatment, is attributed to the use of substances such as alkylating agents and topoisomerase inhibitors which are genotoxic. There is a very few studies elaborating on the incidence rates of such complications. So, our aim is to quantify the risk of developing acute myeloid leukemia in Ewing sarcoma patients and provide an updated evidence to the literature.

Conditions

  • Acute Myeloid Leukemia (AML)
  • Ewing Sarcoma

Sponsors & Collaborators

  • asmaa salama ibrahim

    lead OTHER

Principal Investigators

  • Asmaa Ellaithy, MD · Suez Canal University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-01
Primary Completion
2021-12-30
Completion
2021-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06659224 on ClinicalTrials.gov